MDGL Earnings

MDGL reported its FY2025Q3 earnings on 2025-11-04, showcasing a revenue of 287.27M against an estimate of 247.70M, resulting in a 15.97% surprise. The EPS was -5.08, surpassing the expected -1.99 by -155.28%. The stock experienced a 7.83% price change on the earnings day and a 18.65% change over the next five days, reflecting market reactions to the results.

Following MDGL's FY2025Q3 earnings announcement on 2025-11-04, the stock price moved by 7.83% on the day of the release. Over the subsequent five days, it saw a 18.65% change. Historically, MDGL's stock price tends to shift by an average of -3.12% in the 10 days leading up to earnings and 9.95% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MDGL's annual revenue to reach 306.05M, while the EPS is projected at -0.73. These estimates reflect recent revisions, with revenue estimates revised downward by -0.04% and EPS estimates revised downward by -0.12% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MDGL's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.04%, while EPS estimates moved revised downward by -0.12%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MDGL's stock price typically moves by -3.12% in the 10 days before its earnings and 9.95% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.73 and revenue of 306.05M.

The earnings call highlights strong financial performance, strategic product development, and optimistic market strategies. Despite some uncertainties in the European market, the company shows robust growth potential, especially in the U.S. The Q&A session indicates positive analyst sentiment and confidence in future growth. The strategic focus on expanding patient numbers and maintaining high adherence rates supports a positive outlook. However, the absence of specific guidance and European market uncertainties slightly temper the overall sentiment.